Food and Drug Administration/Xavier University Global Outsourcing Conference, 22412-22413 [2010-9795]
Download as PDF
22412
Federal Register / Vol. 75, No. 81 / Wednesday, April 28, 2010 / Notices
sroberts on DSKD5P82C1PROD with PROPOSALS
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Initial Review Group; Mental
Health Services in Non-Specialty Settings.
Date: June 8–9, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue, NW., Washington, DC 20037.
Contact Person: Aileen Schulte, PhD,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6140, MSC 9608,
Bethesda, MD 20892–9608, 301–443–1225,
aschulte@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Initial Review Group;
Interventions Committee for Adult Disorders.
Date: June 8–9, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: David Sommers, PhD,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892–9606, 301–443–7861,
dsommers@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Initial Review Group; Mental
Health Services in MH Specialty Settings.
Date: June 10, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue, NW., Washington, DC 20037.
Contact Person: Marina Broitman, PhD,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6153, MSC 9608,
Bethesda, MD 20892–9608, 301–402–8152,
mbroitma@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Initial Review Group;
Interventions Committee for Disorders
Involving Children and Their Families.
Date: June 10, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Mar<15>2010
16:04 Apr 27, 2010
Jkt 220001
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: David Sommers, PhD,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892–9606, 301–443–7861,
dsommers@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Time: 12 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Patricia Greenwel, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2178,
MSC 7818, Bethesda, MD 20892, 301–435–
1169, greenwep@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 22, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
Dated: April 22, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–9840 Filed 4–27–10; 8:45 am]
[FR Doc. 2010–9838 Filed 4–27–10; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Food and Drug Administration
Center for Scientific Review; Notice of
Closed Meetings
[Docket No. FDA–2010–N–0001]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group; Biomaterials and Biointerfaces Study
Section.
Date: May 25–26, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Crystal City, 2399 Jefferson
Davis Highway, Arlington, VA 22202.
Contact Person: Steven J Zullo, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5146,
MSC 7849, Bethesda, MD 20892, 301–435–
2810, zullost@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Gastrointestinal Physiology and
Pathophysiology.
Date: May 28, 2010.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Food and Drug Administration/Xavier
University Global Outsourcing
Conference
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public conference.
SUMMARY: The Food and Drug
Administration (FDA), Cincinnati
District, in co-sponsorship with Xavier
University, is announcing a public
conference entitled ‘‘FDA/Xavier
University Global Outsourcing
Conference.’’ This 3-day public
conference for the pharmaceutical
industry includes presentations from
key FDA officials, global regulators, and
industry experts. The conference will
focus on global compliance challenges
associated with pharmaceutical
outsourcing relationships and supply
chain control, as well as expectations
from global regulators. Pharmaceutical
companies and contract organizations
are invited to this conference to address
the issues that reside on both sides. In
addition to expert presentations,
participants will be engaged through
live polling and a small group
discussion session on sharing best
practices with each other.
Dates and Times: The public
conference will be held on June 14 and
15, 2010, from 8 a.m. to 5 p.m. and June
16, 2010, from 8 a.m. to 1 p.m.
Location: The public conference will
be held on the campus of Xavier
E:\FR\FM\28APN1.SGM
28APN1
Federal Register / Vol. 75, No. 81 / Wednesday, April 28, 2010 / Notices
University, 3800 Victory Pkwy.,
Cincinnati, OH 45207, 513–745–3073 or
513–745–3396.
Contact Persons:
For information regarding this notice:
Steven Eastham, Food and Drug
Administration, 6751 Steger Dr.,
Cincinnati, OH 45237, 513–679–2700,
ext. 123, e-mail:
steven.eastham@fda.hhs.gov.
For information regarding the
conference and registration: Marla
Phillips, Xavier University, 3800
Victory Pkwy., Cincinnati, OH 45207,
513–745–3073, e-mail:
phillipsm4@xavier.edu.
Registration: There is a registration
fee. The conference registration fees
cover the cost of the presentations,
training materials, receptions,
22413
breakfasts, lunches, dinners, and dinner
speakers for the 3 days of the
conference. Early registration ends May
14, 2010. Standard registration ends
June 13, 2010. There will be onsite
registration. The cost of registration is as
follows:
TABLE 1.—REGISTRATION FEES1
Attendees
Fees by May 14th
Fees by June 13th
Industry
$995
$1,200
Small Business (< 100 employees)
$800
$1,000
Academic/Government
$600
$700
Student
$200
$250
FDA Employee
Fee waived
Fee waived
1 The
fourth registration from the same company is free.
sroberts on DSKD5P82C1PROD with PROPOSALS
The following forms of payment will
be accepted: American Express, Visa,
Mastercard, and company checks.
To register online for the public
conference, please visit the
‘‘Registration’’ link on the conference
Web site at https://www.XavierGOC.com.
(FDA has verified the Web site address,
but is not responsible for subsequent
changes to the Web site after this
document publishes in the Federal
Register.)
To register by mail, please send your
name, title, firm name, address,
telephone and fax numbers, e-mail, and
payment information for the fee to
Xavier University, Attn: Sue Bensman,
3800 Victory Pkwy., Cincinnati, OH
45207. An e-mail will be sent
confirming your registration.
Attendees are responsible for their
own accommodations. The conference
headquarter hotel is the Downtown
Cincinnati Hilton Netherlands Plaza, 35
West 5th Street, Cincinnati, OH 45202,
513–421–9100. To make reservations
online, please visit the ‘‘Venue/
Logistics’’ link at https://
www.XavierGOC.com.
If you need special accommodations
due to a disability, please contact Marla
Phillips (see Contact Persons) at least 7
days in advance of the conference.
The
public conference helps fulfill the
Department of Health and Human
Services and FDA’s important mission
to protect the public health. The
conference will provide those engaged
in FDA-regulated outsourcing with
information on the following topics:
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
16:04 Apr 27, 2010
Jkt 220001
• FDA Center to present on initiatives
from Congress and FDA, and resulting
impact;
• Global regulator perspective on
global compliance initiatives,
challenges, and expectations;
• FDA Field perspective on the most
common and significant deficiencies
specific to outsourcing relationships;
• Global compliance of
manufacturing in Asia;
• Pharmaceutical companies—how to
manage varying global regulatory
expectations while working with
contractors in various states of
compliance;
• Contract organizations—
compliance strategy for managing global
regulatory requirements while managing
multiple client expectations;
• Contract Organization Selection
Process;
• The Client Selection Process—the
criteria a contract organization should
use to consider saying no to a contract
relationship;
• Regulatory challenges—Drug Master
File Fitness;
• Due diligence audit—how to audit
in 1 day;
• Quality Agreement Development
throughout the product and process
lifecycle;
• Supply Chain Transparency and
Pedigree;
• How to Audit the Supply Chain;
• Rx-360 and International
Pharmaceutical Excipients Council
initiatives—impact to industry;
• Risk-based Performance
Management best practices;
• International Conference on
Harmonisation Triple Q’s (Q8, Q9, and
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Q10)—how quality can drive down the
cost of business, and how innovation
can increase business opportunities;
• Rebuilding the Trust case studies;
and
• Small group discussion on sharing
best practices.
FDA has made education of the drug
and device manufacturing community a
high priority to help ensure the quality
of FDA-regulated drugs and devices.
The conference helps to achieve
objectives set forth in section 406 of the
Food and Drug Administration
Modernization Act of 1997 (21 U.S.C.
393), which includes working closely
with stakeholders and maximizing the
availability and clarity of information to
stakeholders and the public. The
conference also is consistent with the
Small Business Regulatory Enforcement
Fairness Act of 1996 (Public Law 104–
121) by providing outreach activities by
Government agencies to small
businesses.
Dated: April 22, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–9795 Filed 4–27–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
E:\FR\FM\28APN1.SGM
28APN1
Agencies
[Federal Register Volume 75, Number 81 (Wednesday, April 28, 2010)]
[Notices]
[Pages 22412-22413]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-9795]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Food and Drug Administration/Xavier University Global Outsourcing
Conference
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public conference.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA), Cincinnati District,
in co-sponsorship with Xavier University, is announcing a public
conference entitled ``FDA/Xavier University Global Outsourcing
Conference.'' This 3-day public conference for the pharmaceutical
industry includes presentations from key FDA officials, global
regulators, and industry experts. The conference will focus on global
compliance challenges associated with pharmaceutical outsourcing
relationships and supply chain control, as well as expectations from
global regulators. Pharmaceutical companies and contract organizations
are invited to this conference to address the issues that reside on
both sides. In addition to expert presentations, participants will be
engaged through live polling and a small group discussion session on
sharing best practices with each other.
Dates and Times: The public conference will be held on June 14 and
15, 2010, from 8 a.m. to 5 p.m. and June 16, 2010, from 8 a.m. to 1
p.m.
Location: The public conference will be held on the campus of
Xavier
[[Page 22413]]
University, 3800 Victory Pkwy., Cincinnati, OH 45207, 513-745-3073 or
513-745-3396.
Contact Persons:
For information regarding this notice: Steven Eastham, Food and
Drug Administration, 6751 Steger Dr., Cincinnati, OH 45237, 513-679-
2700, ext. 123, e-mail: steven.eastham@fda.hhs.gov.
For information regarding the conference and registration: Marla
Phillips, Xavier University, 3800 Victory Pkwy., Cincinnati, OH 45207,
513-745-3073, e-mail: phillipsm4@xavier.edu.
Registration: There is a registration fee. The conference
registration fees cover the cost of the presentations, training
materials, receptions, breakfasts, lunches, dinners, and dinner
speakers for the 3 days of the conference. Early registration ends May
14, 2010. Standard registration ends June 13, 2010. There will be
onsite registration. The cost of registration is as follows:
Table 1.--Registration Fees\1\
------------------------------------------------------------------------
Attendees Fees by May 14th Fees by June 13th
------------------------------------------------------------------------
Industry $995 $1,200
------------------------------------------------------------------------
Small Business (< 100 $800 $1,000
employees)
------------------------------------------------------------------------
Academic/Government $600 $700
------------------------------------------------------------------------
Student $200 $250
------------------------------------------------------------------------
FDA Employee Fee waived Fee waived
------------------------------------------------------------------------
\1\ The fourth registration from the same company is free.
The following forms of payment will be accepted: American Express,
Visa, Mastercard, and company checks.
To register online for the public conference, please visit the
``Registration'' link on the conference Web site at https://www.XavierGOC.com. (FDA has verified the Web site address, but is not
responsible for subsequent changes to the Web site after this document
publishes in the Federal Register.)
To register by mail, please send your name, title, firm name,
address, telephone and fax numbers, e-mail, and payment information for
the fee to Xavier University, Attn: Sue Bensman, 3800 Victory Pkwy.,
Cincinnati, OH 45207. An e-mail will be sent confirming your
registration.
Attendees are responsible for their own accommodations. The
conference headquarter hotel is the Downtown Cincinnati Hilton
Netherlands Plaza, 35 West 5th Street, Cincinnati, OH 45202, 513-421-
9100. To make reservations online, please visit the ``Venue/Logistics''
link at https://www.XavierGOC.com.
If you need special accommodations due to a disability, please
contact Marla Phillips (see Contact Persons) at least 7 days in advance
of the conference.
SUPPLEMENTARY INFORMATION: The public conference helps fulfill the
Department of Health and Human Services and FDA's important mission to
protect the public health. The conference will provide those engaged in
FDA-regulated outsourcing with information on the following topics:
FDA Center to present on initiatives from Congress and
FDA, and resulting impact;
Global regulator perspective on global compliance
initiatives, challenges, and expectations;
FDA Field perspective on the most common and significant
deficiencies specific to outsourcing relationships;
Global compliance of manufacturing in Asia;
Pharmaceutical companies--how to manage varying global
regulatory expectations while working with contractors in various
states of compliance;
Contract organizations--compliance strategy for managing
global regulatory requirements while managing multiple client
expectations;
Contract Organization Selection Process;
The Client Selection Process--the criteria a contract
organization should use to consider saying no to a contract
relationship;
Regulatory challenges--Drug Master File Fitness;
Due diligence audit--how to audit in 1 day;
Quality Agreement Development throughout the product and
process lifecycle;
Supply Chain Transparency and Pedigree;
How to Audit the Supply Chain;
Rx-360 and International Pharmaceutical Excipients Council
initiatives--impact to industry;
Risk-based Performance Management best practices;
International Conference on Harmonisation Triple Q's (Q8,
Q9, and Q10)--how quality can drive down the cost of business, and how
innovation can increase business opportunities;
Rebuilding the Trust case studies; and
Small group discussion on sharing best practices.
FDA has made education of the drug and device manufacturing
community a high priority to help ensure the quality of FDA-regulated
drugs and devices. The conference helps to achieve objectives set forth
in section 406 of the Food and Drug Administration Modernization Act of
1997 (21 U.S.C. 393), which includes working closely with stakeholders
and maximizing the availability and clarity of information to
stakeholders and the public. The conference also is consistent with the
Small Business Regulatory Enforcement Fairness Act of 1996 (Public Law
104-121) by providing outreach activities by Government agencies to
small businesses.
Dated: April 22, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-9795 Filed 4-27-10; 8:45 am]
BILLING CODE 4160-01-S